What is the appropriate management of hypotension in a patient taking sacubitril/valsartan (Entresto)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Hypotension in Patients Taking Entresto (Sacubitril/Valsartan)

Do not discontinue Entresto for asymptomatic hypotension, as discontinuation is associated with worse outcomes; instead, address reversible causes first and consider temporary dose reduction only if symptomatic hypotension persists despite corrective measures. 1, 2, 3

Initial Assessment and Immediate Management

When hypotension occurs in a patient on Entresto, immediately distinguish between asymptomatic and symptomatic presentations:

  • Asymptomatic hypotension (low blood pressure without symptoms) should NOT lead to drug discontinuation, as patients who stop Entresto after asymptomatic hypotension have significantly worse cardiovascular outcomes compared to those who continue therapy 3, 4
  • Symptomatic hypotension (dizziness, lightheadedness, syncope, or signs of hypoperfusion) requires intervention but still benefits from Entresto continuation when possible 1, 2, 4

Step-by-Step Management Algorithm

Step 1: Correct Reversible Causes First

Before adjusting Entresto, address these common precipitants 1, 2:

  • Volume depletion: Reduce or temporarily hold diuretics if no signs of congestion are present 1
  • Excessive diuresis: Check for orthostatic hypotension and signs of dehydration 2
  • Concomitant antihypertensives: Reduce or discontinue other blood pressure medications (calcium channel blockers, nitrates, alpha-blockers) 1, 2
  • Other causes: Evaluate for hypovolemia, bleeding, infection, or other acute illness 2

Step 2: Medication Prioritization Strategy

The 2025 European Heart Failure Association guidelines provide clear hierarchy for which medications to adjust 1:

  1. Never discontinue first: SGLT2 inhibitors and mineralocorticoid receptor antagonists (MRAs) rarely cause hypotension and should be maintained 1
  2. Adjust cautiously: Entresto is more likely to cause symptomatic hypotension than SGLT2i or MRAs, but its benefits are maintained (or even enhanced) in patients experiencing hypotension 1, 4
  3. Consider reducing: Beta-blockers may be temporarily reduced if symptomatic hypotension persists after addressing other causes 1

Step 3: Entresto Dose Adjustment (Only if Necessary)

Per FDA labeling and clinical guidelines 2:

  • If symptomatic hypotension persists after correcting volume status and adjusting other medications: temporarily reduce Entresto dose or hold briefly 2
  • Starting dose for high-risk patients: Use 24/26 mg twice daily in patients with severe renal impairment (eGFR <30), moderate hepatic impairment, or baseline systolic BP 100-110 mmHg 2, 5
  • Permanent discontinuation is usually NOT required 2

Step 4: Gradual Up-Titration Strategy

For patients requiring dose reduction or those starting at low doses 6, 5, 7:

  • Very low dose initiation (25 mg twice daily) is feasible in patients with baseline systolic BP as low as 100-110 mmHg 6, 5
  • Conservative up-titration over 6 weeks achieves better treatment success (80%) than rapid 3-week titration (69%) in patients with systolic BP 100-110 mmHg 5
  • Target dose achievement: 72-83% of patients with systolic BP ≥100 mmHg can achieve target dose with gradual titration 5

Critical Evidence on Outcomes

The benefits of Entresto are maintained or enhanced in patients experiencing hypotension 4:

  • In PARADIGM-HF, the hazard ratio for cardiovascular death or HF hospitalization with sacubitril/valsartan vs. enalapril was 0.80 in patients without hypotension, 0.87 with asymptomatic hypotension, and 0.51 with symptomatic hypotension 4
  • Patients with lower baseline systolic BP (95-110 mmHg) often experience mild BP increases over time on Entresto, likely reflecting improved cardiac function 1
  • Discontinuation rates were actually lower with Entresto than enalapril even in patients experiencing hypotension 4

Common Pitfalls to Avoid

  • Do not reflexively discontinue Entresto for asymptomatic low BP readings: This leads to worse outcomes 3, 4
  • Do not assume low BP precludes Entresto initiation: Majority of patients with systolic BP ≥100 mmHg tolerate therapy with appropriate titration 5
  • Do not down-titrate guideline-directed medical therapy (GDMT) in patients with major symptoms without specialist consultation: Refer to heart failure specialist or advanced HF program first 1
  • Do not forget that hypotension during run-in phases overestimates real-world rates: PARADIGM-HF excluded 10.4% during run-in, making reported adverse event rates lower than expected in practice 2

Monitoring Requirements

  • Check blood pressure at each dose adjustment and regularly during maintenance 2
  • Monitor renal function and potassium closely, as these may worsen with hypotension 2
  • Assess for signs of hypoperfusion (altered mental status, oliguria, cool extremities) rather than relying solely on BP numbers 1

Special Populations

  • Acute heart failure: In hospitalized patients, initiate SGLT2 inhibitors or low-dose MRAs first after stabilization, then add Entresto cautiously 1
  • Severe renal impairment (eGFR <30): Start at 24/26 mg twice daily 2
  • Moderate hepatic impairment: Start at 24/26 mg twice daily 2
  • Black patients: Higher risk of angioedema but similar hypotension management principles apply 2

References

Related Questions

What is the appropriate protocol for discontinuing losartan and initiating Entresto (sacubitril/valsartan) in a patient with consistently high blood pressure?
In an 80‑plus‑year‑old male with a pacemaker who is taking apixaban, bisoprolol, Entresto (sacubitril/valsartan), and Imdur (isosorbide mononitrate) and now presents with hypotension (systolic 90‑100 mm Hg, diastolic 60‑70 mm Hg), which cardiac medications should be withdrawn or dose‑adjusted and what is the appropriate management?
Can sacubitril‑valsartan (Entresto) be reduced to a once‑daily dose in a heart‑failure patient with normal left‑ventricular size, good wall motion, and preserved systolic function?
When is it appropriate to initiate Entresto (sacubitril/valsartan) at the 97 mg/103 mg dose?
What is the recommended starting dose of sacubitril/valsartan (Entresto) for a heart‑failure patient, considering ACE inhibitor/ARB status, systolic blood pressure ≥100 mm Hg, and eGFR 30–60 mL/min/1.73 m²?
What are the routes of administration for calcitonin and what is the maximum recommended adult dose?
Does Adderall (mixed amphetamine salts) appear as amphetamine on a standard urine drug screen?
Can naproxen cause a localized rash?
How should albumin infiltration from a peripheral intravenous infusion be managed?
What is the appropriate treatment for a fixed drug eruption caused by naproxen?
Can a patient with a cephalexin allergy safely take amoxicillin?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.